Ancora Advisors’s Rhythm Pharmaceuticals RYTM Stock Holding History

Ancora Advisors’s Portfolio RYTM Stock Details RYTM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-60	Closed	-$1K	–	1996
2021 Q1	$1K	Buy	+60	New	+$1.74K	﹤0.01%	1693

Other funds holding RYTM

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Ancora Advisors's RYTM Position: Q2 2021 in Review

Ancora Advisors sold out of Rhythm Pharmaceuticals (RYTM) in Q2 2021, closing a stake of 60 shares — an estimated $1K sold.

Ancora Advisors first reported a position in RYTM in Q1 2021 and held it in 1 quarter. The position peaked at $1K in Q1 2021. 105 funds tracked by Wall St. Rank hold RYTM as of Q2 2021.

Ancora Advisors reported no remaining Rhythm Pharmaceuticals position as of Q2 2021 after selling out during the quarter.
Ancora Advisors sold 60 Rhythm Pharmaceuticals shares in Q2 2021, an estimated $1K.
Ancora Advisors first reported a position in Rhythm Pharmaceuticals in Q1 2021 and held it in 1 quarter.
Ancora Advisors's Rhythm Pharmaceuticals position peaked at $1K in Q1 2021.
105 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q2 2021.

Based on Ancora Advisors's 13F filing for Q2 2021, filed 13 Aug 2021.